Atrasentan: new molecule in the therapy of IgA nephropathy and other glomerulopathies

Czech version

Authors: Silvie Rajnochová Bloudíčková
Authors‘ workplace: Klinika nefrologie TC IKEM, Praha
Published in: Čes. slov. Farm., 2026; 75, 108-111
Category: MEDICAMENT NOVA
doi: https://doi.org/10.36290/csf.2026.019

Overview

Atrasentan, a selective endothelin receptor ET_A antagonist, is a new potential molecule in the treatment of proteinuric glomerulopathies, especially IgA nephropathy. Current studies confirm its benefit in reducing proteinuria. In combination with currently used renoprotective drugs, atrasentan may significantly contribute to reducing renal damage and thus slowing the progression of chronic kidney disease.

Keywords:

chronic kidney disease – glomerulopathy – study – atrasentan – IgA nephropathy – endothelin

Sources

1. Moedt E, Wasehuus VS, Heerspink HJL. Selective endothelin A receptor antagonism in chronic kidney disease: improving clinical application. Nephrol Dial Transplant. 2025;40(Supplement_1):i37-i46. doi: 10.1093/ndt/gfae214.

2. Cheung CK, Barratt J. The Rapidly Changing Treatment Landscape of IgA Nephropathy. Semin Nephrol. 2024;44(5):151573. doi: 10.1016/j.semnephrol.2025.151573.

3. Heerspink HJL, Parving HH, Andress DL, et al. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Lancet. 2019;393(10184):1937-1947. doi: 10.1016/S0140-6736(19)30772-X.

4. Kohan DE, Pritchett Y, Molitch M, et al. Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy. J Am Soc Nephrol. 2011;22(4):763-72. doi: 10.1681/ASN.2010080869.

5. Tian Z, Yang Y, Mei J, et al. Efficacy and safety of endothelin A receptor antagonists in IgA nephropathy: a systematic review and meta-analysis. Clin Kidney J. 2025;18(3):sfaf066. doi: 10.1093/ckj/sfaf066.

6. Keam SJ. Atrasentan: First approval. Drugs 2025; 85 : 1311-1317. doi: 10.1007/s40265-025-02208.

7. Heerspink HJL, Andress DL, Bakris G, et al. Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy. Diabetes Obes Metab. 2018;20(6):1369-1376. doi: 10.1111/dom.13245.

8. Zonnenberg BA, Groenewegen G, Janus TJ, et al. Phase I dose-escalation study of the safety and pharmacokinetics for refractory prostate cancer. Clin Cancer Res 2003; 8(8):2965-72.

9. PharmaTimes. FDA rejects Abbott's prostate cancer drug Xinlay [Internet]. PharmaTimes; 2005 [cited 2026 May 20]. Available from: https://pharmatimes.com/news/fda_rejects_abbotts_prostate_cancer_drug_xinlay_998863/.

10. Trials and Tribulations in Prostate Cancer Xinlay Rejected by US FDA Committee. Pharmaceutical & Diagnostic Innovatio. 2005;3(10):11-13.

11. Waijer SW, Gansevoort RT, Bakris GL, et al. The Effect of Atrasentan on Kidney and Heart Failure Outcomes by Baseline Albuminuria and Kidney Function: A Post Hoc Analysis of the SONAR Randomized Trial. Clin J Am Soc Nephrol. 2021;16(12):1824-1832. doi: 10.2215/CJN.07340521.

12. Heerspink HJL, Kohan DE, de Zeeuw D. New insights from SONAR indicate adding sodium glucose co-transporter 2 inhibitors to an endothelin receptor antagonist mitigates fluid retention and enhances albuminuria reduction. Kidney Int. 2021;99(2):346-349. doi: 10.1016/j.kint.2020.09.026.

13. Gholizadeh Ghozloujeh Z, Selvaskandan H, Wiegley N, et al. IgA Nephropathy: An Overview of the Clinical Trials. Kidney Med. 2025;7(10):101078. doi: 10.1016/j.xkme.2025.101078.

14. Heerspink HJL, Jardine M, Kohan DE, et al. Study Design and Baseline Characteristics of ALIGN, a Randomized Controlled Study of Atrasentan in Patients With IgA Nephropathy. Kidney Int Rep. 2024;10(1):217-226. doi: 10.1016/j.ekir.2024.10.004.

15. Mottl AK, Mastroianni-Kirsztajn G, Noronha IL, et al. Baseline Characteristics of ASSIST: Phase 2 Crossover Trial of Atrasentan in Adults with IgAN on SGLT2 Inhibitors. J Am Soc Nephrol. 2025;36(10S):10.1681/ASN.20251m9dyn78.

16. Heerspink HL, Barratt J, Gorriz Teruel JL, et al. Assist study design: A randomized, double-blind, placebo-controlled, crossover study of atrasentan in patients with IgA nephropathy (IgAN) on SGLT2i. Nephrol Dial Transplant 2023; Volume 38, Issue Supplement_1, doi.org/10.1093/ndt/gfad063c_4341.

17. Kim SG, Inker LA, Packham DK, et al. WCN23-1126 Atrasentan for the treatment of IgA nephropathy: Interim results of the AFFINITY study. Kidney Int Rep. 2023; 8(9):1902. doi.org/10.1016/j.ekir.2023.02.1088.

18. Barratt J, Kim SG, Inker LA, et al. AFFINITY Study: 1-Year Results of Atrasentan in IgA Nephropathy. J Am Soc Nephrol 2024;35(10S):10.1681/ASN.2024sd7jz4q0. doi: 10.1681/ASN.2024sd7jz4q0.

19. Barrat J, VO ND, Lee S, et al. AFFINITY study: 1y results of atrasentan in IgAN patients with UPCR < 1 and ≥1g/g. Abstract #G-447. Am J Kid Dis. 2025; S140-S141. doi: 10.1053/j.ajkd.2025.02.0448.